The blood protein hCAP‐18 in neutropenia: An 18‐month experience of a new ELISA for clinical use

Neutropenia as an isolated clinical finding may include aetiologies ranging from severe disease to a transient condition, and differential diagnosis be challenging. Previous data experience suggest that low levels of the neutrophil-derived protein human 18 kDa cathelicidin antimicrobial (hCAP-18) in blood are predictive more forms neutropenia. The objective this study was present results newly developed ELISA method has been used routine Sweden since 2018 for quantification hCAP-18 plasma. Using method, we report patients with analysed during period presented or undetectable plasma hCAP-18, validating its use screening tool Furthermore, neutropenic group displayed lower compared donors. Within patients, those neutrophil antibodies significantly higher idiopathic By including analysis primary investigation neutropenia, increased accuracy is achieved, thus contributing reduced costs neutropenia management.